TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01252134

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Biotrue multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution
Study: NCT02063087

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Head CT Decision Aid
Description: The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
Study: NCT02340689

Intervention type: OTHER
Intervention: Genetic Analysis
Description: We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
Study: NCT01252134

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Sauflon Synergi multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: OTE Elements multipurpose solution
Description: Contact lens care solution

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses

Intervention type: DEVICE
Group type: OTHER
Intervention: Silicone hydrogel contact lenses (Acuvue Advance)
Description: Commercially marketed contact lenses
Study: NCT03135587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loading level
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loading level
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loading level
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
Study: NCT01471834

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BAROSTIM NEO System

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Medical Management
Study: NCT00172068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoledronic acid + Calcium/Vitamin D

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid + Calcium/Vitamin D
Study: NCT03245060

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted Solution Focused Brief Therapy
Description: Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
Study: NCT04163471

Intervention type: DEVICE
Intervention: Radial artery mechanical compression for hemostasis
Description: Transradial hemostasis following arterial catheterization procedures

Intervention type: DEVICE
Intervention: Radial artery mechanical compression for hemostasis
Description: Transradial hemostasis following arterial catheterization procedures
Study: NCT03091712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glooko Mobile Insulin Dosing System(MIDS)
Description: Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
Study: NCT04013074

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transjugular Intrahepatic Portosystemic Shunt
Description: Transjugular Intrahepatic Portosystemic Shunt
Study: NCT03135587

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Loading level
Description: Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
Study: NCT04013074

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Therapy only included as per requirement nutritional therapy (high calorie intake- 2400 Kcal/ day) as and when required LVP and albumin infusion and diuretics.
Study: NCT00111566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: eptifibatide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eptifibatide
Study: NCT00749411

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK233705/GW642444
Description: The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
Study: NCT00426530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus (RAD001)
Study: NCT00651287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 20 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 20 mg plus hydrochlorothiazide 12.5 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
Study: NCT00651287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: quinapril 40 mg
Description: Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
Study: NCT03690245

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Initiation of Resuscitation While Attached to the Cord
Description: Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Initiation of Resuscitation While Attached to the Cord
Description: Infants will receive active resuscitative care according to the Neonatal Resuscitation Program (NRP) guidelines including warmth, dry, suctioning, oxygen, and respiratory support using iNSPiRE platform for 120 seconds while attached to the cord.
Study: NCT01829451

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gel
Description: Hyaluronic acid gel is placed into the uterus after endometrial ablation~--------------------------------------------------------------------------------
Study: NCT03397953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine
Description: Vinorelbine will be used 25mg/m2/week, rest for 1 week after 3 weeks of continuous use, 4 weeks will be a course. After 1 week there will be a simple assessment, after 2 weeks will be a comprehensive assessment. If the patient got disease progression or partial response/stable disease, he/she would be removed from this trial.
Study: NCT03367689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib 300 mg twice a day (orally) beginning on Day 1 and continuing through Day 28 of every 28-day cycle.
Study: NCT04094740

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jet Injector without A Needle
Description: Patients in the experimental group will use a needle - free jet injector to inject insulin, which delivers insulin at a high velocity into subcutaneous tissue and dispenses insulin over a larger area than a syringe.
Study: NCT00480324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix
Description: Two-dose oral vaccination.
Study: NCT02327169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.
Study: NCT00480324

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration.
Study: NCT04382430

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided venous access
Description: Each physician/ provider will perform 2 assisted ultrasound (US) guided venous access and pocket creation for cardiac device implant and 10 solo ultrasound guided cardiac device implant.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional technique
Description: Physician will perform 5 cardiac device implant using conventional technique of venous access and pocket creation
Study: NCT03956589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orkambi
Description: Open label of Orkambi treatment during 3 months
Study: NCT01191476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalational Induction and Maintenance
Description: Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Target Controlled Infusion for Induction and Maintenance
Description: Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance
Description: Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
Study: NCT03297294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMA401
Description: capsules, oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo to EMA401 capsules, oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to EMA401 capsules, oral
Study: NCT02127073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin
Description: Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
Study: NCT02244424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tools for Teen Moms
Description: The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life.
Study: NCT02754284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fat transplantation
Description: Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Functional collagen scaffold transplantation
Description: Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
Study: NCT02488824

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Warm Temperature
Description: Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Warm Temperature
Description: Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
Study: NCT00689845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bleomycin sulfate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study: NCT01291004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desogestrel/ethinyl estradiol and ethinyl estradiol
Description: Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
Study: NCT00689845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV
Study: NCT02327169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.
Study: NCT00689845

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT03015922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide or Pomalidomide
Description: Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: REOLYSIN
Description: Patients will receive Reolysin alongside either lenalidomide or pomalidomide
Study: NCT02401750

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Naltrexone (a)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Naltrexone (b)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matches both experimental drugs
Study: NCT00689845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study: NCT02327169

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN2480
Description: MLN2480 tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MLN0128
Description: MLN0128 capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alisertib
Description: Alisertib tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan IV infusion.
Study: NCT01334255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iSONEP (sonepcizumab/LT1009)
Description: Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iSONEP (sonepcizumab/LT1009)
Description: Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
Study: NCT00737789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine slow-release granules
Description: Mesalazine 2g Sachet prolonged release granules, administered orally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine slow-release granules
Description: Mesalazine 2g Sachet prolonged release granules, administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesalazine liquid enema
Description: 1g mesalazine liquid enema, administered topically once a day in the evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine liquid enema
Description: 1g mesalazine liquid enema, administered topically once a day in the evening.
Study: NCT01291004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 28-day drospirenone oral contraceptive
Description: Drospirenone/ethinyl estradiol 0.3/0.02 mg
Study: NCT02946203

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Barium Sulfate
Description: Barium Sulfate Oral Contrast-VoLumen

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored beverage Oral Contrast
Description: Flavored beverage for neutral abdominal/pelvic imaging
Study: NCT01349478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LOKOMAT
Description: Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
Study: NCT00427037

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 50,000 IU weekly by mouth

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: identical placebo pill orally by mouth
Study: NCT04871620

Intervention type: DIAGNOSTIC_TEST
Intervention: >15% SV increase during fluid challenge
Description: The stroke volume will be measured before and after 15 minutes fluid challenge with crystalloids
Study: NCT00809822

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPB-01
Description: Intravenous immunoglobulin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Physiological saline
Study: NCT02055508

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Care-Management-Phone-Calls

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Care-Management-Phone-Calls